Philip Kuball, MD

Resident in the Department of Neurology at NYU Langone Health.

Articles by Philip Kuball, MD

Evaluating Safety and Early Outcomes of Lecanemab Treatment for Alzheimer Disease: Philip Kuball, MD

ByPhilip Kuball, MD,Luke Halpern,Isabella Ciccone, MPH

April 18th 2025

The resident in the Department of Neurology at NYU Langone Health discussed the preliminary findings of a 9-month study on lecanemab recently presented at the 2025 AAN Annual Meeting. [WATCH TIME: 2 minutes]

Philip Kuball, MD

Articles by Philip Kuball, MD

Evaluating Safety and Early Outcomes of Lecanemab Treatment for Alzheimer Disease: Philip Kuball, MD

Latest Updated Articles

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Earlier Initiation of Pimavanserin Leads to Better Improvement of Parkinson Disease Psychosis Symptoms

MDS Congress 2025: Top Expert Interviews and Key Takeaways

A Step Forward in Multiple System Atrophy: Phase 2 Findings Reinforce ATH434’s Disease-Modifying Potential

Increasing Early Awareness of Child Neurology as a Potential Career Path: Miya Bernson-Leung, MD, EdM

Integrating Nutrition and Lifestyle Strategies in Pediatric Multiple Sclerosis Management